secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-09-28T20:05:33+00:00
Accession:  0001213900-26-104034
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Tempest CFO Rossettos resigns; Constance Ames named CFO; Freda-Smith joins board as Audit Chair
--------------------------------------------------------------------------------

- Related-party Master Services Agreement with Factor Bioscience: CEO Matt Angel controls Factor and owns 34.2% of Tempest; expected fees of $5.0M/year paid in $416,667 monthly installments.
- Work Order No. 1 covers development of in vivo CAR-T therapies; either party may terminate the MSA or work order on 30 days' notice; Tempest has three one-month suspension rights.
- CFO Nicholas Rossettos resigned effective immediately on Sept 22, 2026; Constance Ames named CFO, principal financial and accounting officer, treasurer and corporate secretary.
- Nancy Freda-Smith, 54, former Chief Audit and Risk Officer at Ralph Lauren, appointed Class III director and Chair of the Audit Committee; receives a 25,000-share option award.
- Nasdaq told Tempest on May 22, 2026 it was out of compliance over multiple board vacancies; after adding Freda-Smith, Dr. Yee and Mr. Richey, the board says it is now in full compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000121390026104034/0001213900-26-104034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000121390026104034/ea0306741-8k_tempest.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-104034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer